Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

CANNANNEW REPORT

BERWYN, Pa.–(BUSINESS WIRE)–#pharma–Virpax® Pharmaceuticals, Inc. (“Virpax”), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H.C. Wainwright event from Monday, January 10th through Thursday, January 13th starting at 7:00 a.m. ET. Anthony Mack, Chairman & CEO of Virpax, will be giving the presentation. Management will also be hosting virtual one-on-one meetings on Monday, January 10th and Tuesday, January 11th. Event: Virpax Pharma Presentation at the H.C. Wainwright BioConnect Virtual Conference Date: Monday, January 10th through Thursday, January 13th Time: On Demand from 7:00 a.m. ET to 7:00 p.m. ET daily Webcast: Register Here A replay of the presentation will also be available for 90 days on the Virpax website. For more information on the H.C. Wainwright BioConnect Conference or to schedule a one-on-one meeting with Virpax management, please contact your conference representative or you may also email your request to betsy.brod@affinitygrowth.com or call (212) 661-2231. About Virpax Pharmaceuticals Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval of its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal Molecular-Envelope Technology (MET) enkephalin formulation being developed for the management of acute and chronic pain, including pain associated with cancer, as well as post-traumatic stress disorder (PTSD) under the name PES200. MET technology is also used in AnQlar™, a candidate to inhibit viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol…

Excerpt only …
READ MORE BELOW
Source : Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.